—A large data analysis found a significantly heightened relative risk of optic neuritis in NMOSD, MOGAD, and other inflammatory diseases, supporting prompt evaluation of visual complaints in these ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid kinase-2 activator OCS-05 protected nerve cells and improved vision in patients ...

A nationwide cohort study of more than 4 million adults showed that people with allergic diseases were nearly one third more likely to develop optic neuritis than those without such conditions, with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 2 ACUITY trial met its primary safety endpoint ...

Please provide your email address to receive an email when new articles are posted on . One physician said intravenous corticosteroids are useful for treating optic neuritis. Another argued ...

Genetic analysis combined with consideration of other risk factors could significantly improve early distinction between people with optic neuritis who are likely to develop multiple sclerosis (MS), ...

ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...